Updates are available Correction dated 2025-08-26

Article History

Received: 17 February 2025

Accepted: 14 April 2025

First Online: 6 May 2025

Change Date: 26 August 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13555-025-01527-7

Declarations

:

: Mark Lebwohl is an Editorial Board member of Dermatology and Therapy who was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. He is an employee of Mount Sinai; receives research funds from AbbVie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio Inc., Apogee, Arcutis, AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. André Carvalho acted as a consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen Pharmaceuticals Inc., LEO Pharma, Novartis, Sun Pharma, and UCB. Akihiko Asahina has received honoraria and/or research grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho Co., Ltd., Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sun Pharma, Taiho Pharma, Torii Pharmaceutical Co., Ltd., and UCB. Jianzhong Zhang reports nothing to disclose. Mir Sohail Fazeli, Ellen Kasireddy, and Paul Serafini report employment with Evidinno Outcomes Research Inc. Thomas Ferro and Ranga Gogineni report employment with Sun Pharmaceutical Industries Inc. Diamant Thaçi is an advisor, speaker, or consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Janssen, Kyowa Kirin, L'Oréal, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi/Genzyme, and UCB.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.